Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services.
Industry sector: Medical
Sector classification: Pharmaceutical preparations
Deep Learning based analysis and prediction model for Zoetis Inc. (ZTS) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.
Model is in the production pipeline since Oct. 22, 2015.
Market data for ZTS model training are being downloaded from the
Quandl premium datasets on a daily basis.
Risks related to the novel coronavirus disease 2019 (COVID-19) caused by the virus named “SARS-CoV-2” are
accounted for in this model in the form of the historical data coincided with outbreaks and other
global events in the past used to train ML prediction model for ZTS.
Model is being retrained on a daily basis.
| Float | 484M |
| P/E | 30.50 |
| Shares Outstanding | 485M |
| % Held by Insiders | 0.35% |
| % Held by Institutions | 92.60% |
| EPS (last reported FY) | $2.40 |
| EPS (last reported Q) | $0.75 |
| EPS, estimated (last reported Q) | $0.70 |
| Total revenues | $5 B |
| Net income | $1 B |